# High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4

> **NCT00662220** · PHASE3 · TERMINATED · sponsor: **Foundation for Liver Research** · enrollment: 110 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** ribavirin
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT00662220
- **Lead sponsor:** Foundation for Liver Research
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2013-06
- **Final completion:** 2013-11
- **Target enrollment:** 110 (ACTUAL)
- **Why stopped:** Due to the arrival of DAAs replacing standard of care for genotype 1 patients the VIRID study had to be terminated.
- **Last updated:** 2014-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00662220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00662220, "High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00662220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*